FN-1501

N/A

Report date: 2022/06/10 14:43:39
NME

Base Information

Drug NameFN-1501
Drug Alias NameFN-1501LT-171-861
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 6 inhibitorsCyclin-dependent kinase 4 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors +[4] 
TargetsCyclin-dependent kinase 6Tyrosine-protein kinase receptor FLT3Cyclin-dependent kinase 4 +[4] 
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesChina Pharmaceutical UniversityShanghai Fosun Pharmaceutical Industrial Development Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical Industrial Development Co Ltd
Inactive CompaniesShanghai Suntech Pharmaceutical Co LtdChina Pharmaceutical University
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsSolid tumoursLeukemia, Myeloid, AcuteNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A